AFFiRiS AG - AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS

Vienna, 23rd June 2009. MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity accolade antagonism hosted by the industry annual Boerse-Express and Junge Industrie. The accolade recognised the abiding affiliation amid the German adventure armamentarium and the Austrian biotechnology aggregation as able-bodied as a EUR 430 actor accord amid AFFiRiS and GSK Biologicals.

Last Tuesday MIG Fonds and AFFiRiS AG were awarded aboriginal abode in the Venture Capital and Private Equity (VC / PE) awards of the Austrian industry annual Boerse-Express.com and their co-sponsors Junge Industrie. The winners are called afterward a appropriate alternative action that combines the perspectives of the magazine's readers and called experts, who appraise accumulated success belief from altered perspectives. This year, an investment accord that has been abounding for both adventure ally was recognised and the accent of VC costs for the start-up aeon of avant-garde businesses was thereby recognised.

Dr. Walter Schmidt, co-founder and CEO of AFFiRiS AG, commented that the VC / PE awards "have a actual appropriate acceptation for the basic investment bazaar in Austria because they authenticate the basic action of VC in the development of able high-tech businesses. In our case, three years ago MIG Fonds started to advance a absolute of EUR 11.5 million. Without this capital, our licensing accord with GSK Biologicals three years after would not accept been possible. This accord is for up to EUR 430 actor in upfront and anniversary payments for our Alzheimer’s vaccines. MIG Fonds' accommodation to advance has accordingly already been amiable for anybody involved."

Based on the MIG Fonds investment, AFFiRiS AG was able to advance ist AFFITOME® technology, which delivers avant-garde vaccines with actual specific properties. The close has already appear the development of candidates for ameliorative vaccines adjoin Alzheimer's, Parkinson's and atherosclerosis - in added words, adjoin diseases that accept so far seemed clashing for analysis by vaccination, but that represent markets account billions. Vaccine candidates for four added bearding abiding diseases are currently accepting developed by AFFiRiS AG.

Asked about the success adventure of AFFiRiS AG and the accepted award, Andreas Höfler of Alfred Wieder AG said: "We are actual appreciative of this award. Good investment tends to not alone advance advances in technology, but aswell to advance individuals and aims that are as abstracted as they are clear. Our MIG armamentarium managers aswell pay accurate absorption to ensuring that the ambition markets of our abeyant investees are of a acceptable size, and that the businesses we accounts accept the abeyant to become all-embracing bazaar leaders. We recognised this abeyant in AFFiRiS three years ago - the aboriginal big pharma accord and the accepted accolade affirm our antecedent analysis."

About AFFiRiS AG (as at June 2009)
AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are acclimated to amusement Alzheimer's disease, atherosclerosis, Parkinson's ache and added diseases that actively crave a medical band-aid and which accept ample bazaar potential. Alzheimer's ache is currently the arch adumbration and two abeyant articles are in the final stages of analytic appearance I studies. In October 2008, the aggregation succeeded in accepting GlaxoSmithKline Biologicals as its licensing accomplice for the Alzheimer's vaccine. The arrangement anticipates milestone-dependent
payments of up to EUR 430 million. AFFiRiS currently employs 50 awful able agents and afresh added an added 1,100 sqm to its bounds at the St. Marx campus in Vienna, Austria (www.affiris.com).

Contact for AFFiRiS AG:
Mag. Agnes Meyer
Karl-Farkas-Gasse 22
1030 Vienna
Austria
T +43 / 1 / 798 15 75 - 390
E agnes.meyer@affiris.com

Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus Vienna Biocenter 2
1030 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at